Phase 1 Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing on Enzalutamide.

Wassim Abida Andrew W Hahn Neal D Shore Archana M Agarwal Paul R Sieber Matthew R Smith Tanya Barauskas Dorff J Paul Monk Matthew B Rettig Rupal Patel Anne Page Maureen Duff Rongda Xu Jian Wang Shravani R Barkund Aleksandr Pankov Amber Wang Melissa R Junttila Pratik S Multani Anneleen Daemen Edna Chow-Maneval Christopher L Logothetis Michael J Morris

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Although the combination of ORIC-101 and enzalutamide demonstrated an acceptable tolerability profile, GR target inhibition with ORIC-101 did not produce clinical benefit in men with metastatic prostate cancer resistant to enzalutamide.

Keyphrases

prostate cancer
radical prostatectomy
open label
squamous cell carcinoma
small cell lung cancer
randomized controlled trial
placebo controlled
middle aged
study protocol